FREE SHIPPING over $40
OVER 9000 FIVE-STAR REVIEWS
5% OFF ALL SUBSCRIPTIONS
100% HAPPINESS GUARANTEE
Analyze Diet
0
Home / Equine Research Bank / J Stem Cells Regen Med / Cathepsin K Localizes to Equine Bone In Vivo and Inhibits Bo...
Journal of stem cells & regenerative medicine2017; 13(2); 45-53; doi: 10.46582/jsrm.1302008

Cathepsin K Localizes to Equine Bone In Vivo and Inhibits Bone Marrow Stem and Progenitor Cells Differentiation In Vitro.

Abstract: Selective inhibition of Cathepsin K (CatK) has a promising therapeutic potential for diseases associated with bone loss and osseous inflammation, such as osteoarthritis, periodontitis, and osteoporosis. In horses, stress-related bone injuries are common and accompanied by bone pain and inflammation resulting in excessive bone resorption and periostitis. VEL-0230 is a highly selective inhibitor of CatK that significantly decreased bone resorption and increased bone formation biomarkers. The goal of this study was to demonstrate the presence of CatK in equine bone and a simultaneous influence on the bone marrow cellular components including function and differentiation. Our objectives were: 1) to investigate the tissue localization of CatK protein in equine bone using immunohistochemistry, and 2) to determine the effect of CatK inhibition on osteoclastogenic, chondrogenic and osteogenic differentiation potential of equine stem and progenitor cells using histochemical staining and differentiation-related gene expression analyses. Bone biopsies, harvested from the tuber coxae and proximal phalanx of six healthy horses, were processed for immunostaining against CatK. Sternal bone marrow aspirates were cultured in 0, 1, 10, or 100 μM of VEL-0230 and subsequent staining scoring and gene expression analyses performed. All cells morphologically characterized as osteoclasts and moderate number of active bone lining osteoblasts stained positive for CatK. Histochemical staining and gene expression analyses revealed a significant increase in the osteoclastogenic, chondrogenic and osteogenic differentiation potential of equine bone marrow cells, which was VEL-0230-concentration dependent for the latter two. These results suggested that CatK inhibition may have anabolic effects on bone and cartilage regeneration that may be explained as a feedback response to CatK depletion. In conclusion, the use of CatK inhibition to reduce inflammation and associated bone resorption in equine osseous disorders may offer advantages to other therapeutics that would require further study.
Get Full Text
Publication Date: 2017-12-18 PubMed ID: 29391749PubMed Central: PMC5786646DOI: 10.46582/jsrm.1302008Google Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
LinkedInCopy
  • Journal Article

Summary

This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.

The research investigates how an inhibitor of Cathepsin K, a protein linked to bone loss and inflammation, may aid in treating equine bone injuries by enhancing bone and cartilage regeneration. The study examined where this protein is found in horse bones and the effect of its inhibition on various differentiation potentials of equine stem and progenitor cells.

Objective and Methodology

  • The primary objective of the study was to understand the effects of Cathepsin K (CatK) inhibition on bone marrow cellular components, focusing on their function and differentiation in equine bones.
  • Research was carried out in two stages, firstly locating CatK protein in equine bone via immunohistochemistry; secondly, studying the effects of CatK inhibition on the osteoclastogenic, chondrogenic, and osteogenic differentiation potential of equine stem and progenitor cells.
  • The study used VEL-0230, a selective inhibitor of CatK, and analyzed its concentration-dependent effects on cell differentiation.

Finding and Implications

  • Cells known as osteoclasts and a moderate number of bone-producing osteoblasts tested positive for CatK.
  • The analysis of VEL-0230 revealed a significant increase in the osteoclastogenic, chondrogenic, and osteogenic differentiation potential of equine bone marrow cells, indicating that CatK inhibition may enhance bone and cartilage regeneration.
  • The inhibitive action of VEL-0230 on CatK was found to be concentration-dependent for chondrogenic and osteogenic differentiation potentials.
  • The researchers suggest that the feedback response to CatK depletion due to the use of the inhibitor could explain these anabolic effects on bone and cartilage regeneration.
  • The use of CatK inhibition could deliver therapeutic benefits to treat inflammation and associated bone resorption in equine bones that might surpass other current therapies. However, more studies are needed to understand these potential benefits further.

Cite This Article

APA
Hussein H, Boyaka P, Dulin J, Russell D, Smanik L, Azab M, Bertone AL. (2017). Cathepsin K Localizes to Equine Bone In Vivo and Inhibits Bone Marrow Stem and Progenitor Cells Differentiation In Vitro. J Stem Cells Regen Med, 13(2), 45-53. https://doi.org/10.46582/jsrm.1302008

Publication

Journal of stem cells & regenerative medicine
ISSN: 0973-7154
NlmUniqueID: 101552911
Country: India
Language: English
Volume: 13
Issue: 2
Pages: 45-53

Researcher Affiliations

Hussein, Hayam
  • Department of Veterinary Clinical Sciences, College of Veterinary Medicine, The Ohio State University, Columbus, OH, USA.
Boyaka, Prosper
  • Department of Veterinary Biosciences, College of Veterinary Medicine, The Ohio State University, Columbus, OH, USA.
Dulin, Jennifer
  • Department of Veterinary Clinical Sciences, College of Veterinary Medicine, The Ohio State University, Columbus, OH, USA.
Russell, Duncan
  • Department of Veterinary Biosciences, College of Veterinary Medicine, The Ohio State University, Columbus, OH, USA.
Smanik, Lauren
  • Department of Veterinary Clinical Sciences, College of Veterinary Medicine, The Ohio State University, Columbus, OH, USA.
Azab, Mohamed
  • Department of Veterinary Clinical Sciences, College of Veterinary Medicine, The Ohio State University, Columbus, OH, USA.
Bertone, Alicia L
  • Department of Veterinary Clinical Sciences, College of Veterinary Medicine, The Ohio State University, Columbus, OH, USA.
  • Department of Veterinary Biosciences, College of Veterinary Medicine, The Ohio State University, Columbus, OH, USA.

References

This article includes 45 references
  1. Mukherjee K, Chattopadhyay N. Pharmacological inhibition of cathepsin K: A promising novel approach for postmenopausal osteoporosis therapy.. Biochem Pharmacol 2016 Oct 1;117:10-9.
    pubmed: 27106079doi: 10.1016/j.bcp.2016.04.010google scholar: lookup
  2. Russell RGG, Tsoumpra MK, Lawson MA, Chantry AD, Ebetino FH, Pazianas M. Antiresorptives. The Duration and Safety of Osteoporosis Treatment 2016;pp. 17–36.
  3. McDougall JJ, Schuelert N, Bowyer J. Cathepsin K inhibition reduces CTXII levels and joint pain in the guinea pig model of spontaneous osteoarthritis.. Osteoarthritis Cartilage 2010 Oct;18(10):1355-7.
    pubmed: 20692355doi: 10.1016/j.joca.2010.07.014google scholar: lookup
  4. Svelander L, Erlandsson-Harris H, Astner L, Grabowska U, Klareskog L, Lindstrom E, Hewitt E. Inhibition of cathepsin K reduces bone erosion, cartilage degradation and inflammation evoked by collagen-induced arthritis in mice.. Eur J Pharmacol 2009 Jun 24;613(1-3):155-62.
    pubmed: 19358841doi: 10.1016/j.ejphar.2009.03.074google scholar: lookup
  5. Asagiri M, Hirai T, Kunigami T, Kamano S, Gober HJ, Okamoto K, Nishikawa K, Latz E, Golenbock DT, Aoki K, Ohya K, Imai Y, Morishita Y, Miyazono K, Kato S, Saftig P, Takayanagi H. Cathepsin K-dependent toll-like receptor 9 signaling revealed in experimental arthritis.. Science 2008 Feb 1;319(5863):624-7.
    pubmed: 18239127doi: 10.1126/science.1150110google scholar: lookup
  6. Hao L, Chen J, Zhu Z, Reddy MS, Mountz JD, Chen W, Li YP. Odanacatib, A Cathepsin K-Specific Inhibitor, Inhibits Inflammation and Bone Loss Caused by Periodontal Diseases.. J Periodontol 2015 Aug;86(8):972-83.
    pmc: PMC4648620pubmed: 25879791doi: 10.1902/jop.2015.140643google scholar: lookup
  7. Hirai T, Kanda T, Sato K, Takaishi M, Nakajima K, Yamamoto M, Kamijima R, Digiovanni J, Sano S. Cathepsin K is involved in development of psoriasis-like skin lesions through TLR-dependent Th17 activation.. J Immunol 2013 May 1;190(9):4805-11.
    pubmed: 23543761doi: 10.4049/jimmunol.1200901google scholar: lookup
  8. Hussein H, Ishihara A, Menendez M, Bertone A. Pharmacokinetics and bone resorption evaluation of a novel Cathepsin K inhibitor (VEL-0230) in healthy adult horses.. J Vet Pharmacol Ther 2014 Dec;37(6):556-64.
    pubmed: 24731241doi: 10.1111/jvp.12131google scholar: lookup
  9. Hussein H, Boyaka P, Dulin J, Bertone A. Cathepsin K inhibition renders equine bone marrow nucleated cells hypo-responsive to LPS and unmethylated CpG stimulation in vitro.. Comp Immunol Microbiol Infect Dis 2016 Apr;45:40-7.
    pubmed: 27012920doi: 10.1016/j.cimid.2016.02.005google scholar: lookup
  10. Hussein H, Dulin J, Smanik L, Drost WT, Russell D, Wellman M, Bertone A. Repeated oral administration of a cathepsin K inhibitor significantly suppresses bone resorption in exercising horses with evidence of increased bone formation and maintained bone turnover.. J Vet Pharmacol Ther 2017 Aug;40(4):327-334.
    pubmed: 27885686doi: 10.1111/jvp.12368google scholar: lookup
  11. Drake FH, Dodds RA, James IE, Connor JR, Debouck C, Richardson S, Lee-Rykaczewski E, Coleman L, Rieman D, Barthlow R, Hastings G, Gowen M. Cathepsin K, but not cathepsins B, L, or S, is abundantly expressed in human osteoclasts.. J Biol Chem 1996 May 24;271(21):12511-6.
    pubmed: 8647859doi: 10.1074/jbc.271.21.12511google scholar: lookup
  12. Hummel KM, Petrow PK, Franz JK, Müller-Ladner U, Aicher WK, Gay RE, Brömme D, Gay S. Cysteine proteinase cathepsin K mRNA is expressed in synovium of patients with rheumatoid arthritis and is detected at sites of synovial bone destruction.. J Rheumatol 1998 Oct;25(10):1887-94.
    pubmed: 9779840
  13. Muir P, Schamberger GM, Manley PA, Hao Z. Localization of cathepsin K and tartrate-resistant acid phosphatase in synovium and cranial cruciate ligament in dogs with cruciate disease.. Vet Surg 2005 May-Jun;34(3):239-46.
    pubmed: 16115080doi: 10.1111/j.1532-950x.2005.00036.xgoogle scholar: lookup
  14. Uusitalo H, Hiltunen A, Söderström M, Aro HT, Vuorio E. Expression of cathepsins B, H, K, L, and S and matrix metalloproteinases 9 and 13 during chondrocyte hypertrophy and endochondral ossification in mouse fracture callus.. Calcif Tissue Int 2000 Nov;67(5):382-90.
    pubmed: 11136537doi: 10.1007/s002230001152google scholar: lookup
  15. Mandelin J, Hukkanen M, Li TF, Korhonen M, Liljeström M, Sillat T, Hanemaaijer R, Salo J, Santavirta S, Konttinen YT. Human osteoblasts produce cathepsin K.. Bone 2006 Jun;38(6):769-77.
    pubmed: 16337236doi: 10.1016/j.bone.2005.10.017google scholar: lookup
  16. Vinardell T, Dejica V, Poole AR, Mort JS, Richard H, Laverty S. Evidence to suggest that cathepsin K degrades articular cartilage in naturally occurring equine osteoarthritis.. Osteoarthritis Cartilage 2009 Mar;17(3):375-83.
    pubmed: 18809344doi: 10.1016/j.joca.2008.07.017google scholar: lookup
  17. Gray AW, Davies ME, Jeffcott LB. Localisation and activity of cathepsins K and B in equine osteoclasts.. Res Vet Sci 2002 Apr;72(2):95-103.
    pubmed: 12027589doi: 10.1053/rvsc.2001.0522google scholar: lookup
  18. Fortier LA, Potter HG, Rickey EJ, Schnabel LV, Foo LF, Chong LR, Stokol T, Cheetham J, Nixon AJ. Concentrated bone marrow aspirate improves full-thickness cartilage repair compared with microfracture in the equine model.. J Bone Joint Surg Am 2010 Aug 18;92(10):1927-37.
    pubmed: 20720135doi: 10.2106/jbjs.i.01284google scholar: lookup
  19. Godwin EE, Young NJ, Dudhia J, Beamish IC, Smith RK. Implantation of bone marrow-derived mesenchymal stem cells demonstrates improved outcome in horses with overstrain injury of the superficial digital flexor tendon.. Equine Vet J 2012 Jan;44(1):25-32.
    pubmed: 21615465doi: 10.1111/j.2042-3306.2011.00363.xgoogle scholar: lookup
  20. Herthel DJ. Enhanced suspensory ligament healing in 100 horses by stem cells and other bone marrow components. AAEP proceedings 2001.
  21. Tidball JG, Villalta SA. Regulatory interactions between muscle and the immune system during muscle regeneration.. Am J Physiol Regul Integr Comp Physiol 2010 May;298(5):R1173-87.
    pmc: PMC2867520pubmed: 20219869doi: 10.1152/ajpregu.00735.2009google scholar: lookup
  22. Liu Y, Wang L, Kikuiri T, Akiyama K, Chen C, Xu X, Yang R, Chen W, Wang S, Shi S. Mesenchymal stem cell-based tissue regeneration is governed by recipient T lymphocytes via IFN-γ and TNF-α.. Nat Med 2011 Nov 20;17(12):1594-601.
    pmc: PMC3233650pubmed: 22101767doi: 10.1038/nm.2542google scholar: lookup
  23. Mourkioti F, Rosenthal N. IGF-1, inflammation and stem cells: interactions during muscle regeneration.. Trends Immunol 2005 Oct;26(10):535-42.
    pubmed: 16109502doi: 10.1016/j.it.2005.08.002google scholar: lookup
  24. Sotiropoulou PA, Perez SA, Gritzapis AD, Baxevanis CN, Papamichail M. Interactions between human mesenchymal stem cells and natural killer cells.. Stem Cells 2006 Jan;24(1):74-85.
    pubmed: 16099998doi: 10.1634/stemcells.2004-0359google scholar: lookup
  25. Bratthauer GL. The avidin-biotin complex (ABC) method and other avidin-biotin binding methods.. Methods Mol Biol 2010;588:257-70.
    pubmed: 20012837doi: 10.1007/978-1-59745-324-0_26google scholar: lookup
  26. Takayanagi H. Osteoimmunology: shared mechanisms and crosstalk between the immune and bone systems.. Nat Rev Immunol 2007 Apr;7(4):292-304.
    pubmed: 17380158doi: 10.1038/nri2062google scholar: lookup
  27. Bühling F, Reisenauer A, Gerber A, Krüger S, Weber E, Brömme D, Roessner A, Ansorge S, Welte T, Röcken C. Cathepsin K--a marker of macrophage differentiation?. J Pathol 2001 Oct;195(3):375-82.
    pubmed: 11673837doi: 10.1002/path.959google scholar: lookup
  28. Grant BD, Donaldson JG. Pathways and mechanisms of endocytic recycling.. Nat Rev Mol Cell Biol 2009 Sep;10(9):597-608.
    pmc: PMC3038567pubmed: 19696797doi: 10.1038/nrm2755google scholar: lookup
  29. Vico L, Collet P, Guignandon A, Lafage-Proust MH, Thomas T, Rehaillia M, Alexandre C. Effects of long-term microgravity exposure on cancellous and cortical weight-bearing bones of cosmonauts.. Lancet 2000 May 6;355(9215):1607-11.
    pubmed: 10821365doi: 10.1016/s0140-6736(00)02217-0google scholar: lookup
  30. Sukhova GK, Shi GP, Simon DI, Chapman HA, Libby P. Expression of the elastolytic cathepsins S and K in human atheroma and regulation of their production in smooth muscle cells.. J Clin Invest 1998 Aug 1;102(3):576-83.
    pmc: PMC508918pubmed: 9691094doi: 10.1172/jci181google scholar: lookup
  31. Bühling F, Waldburg N, Gerber A, Häckel C, Krüger S, Reinhold D, Brömme D, Weber E, Ansorge S, Welte T. Cathepsin K expression in human lung. Cellular Peptidases in Immune Functions and Diseases 2: 2002;pp. 281–6.
  32. Mulari MT, Qu Q, Härkönen PL, Väänänen HK. Osteoblast-like cells complete osteoclastic bone resorption and form new mineralized bone matrix in vitro.. Calcif Tissue Int 2004 Sep;75(3):253-61.
    pubmed: 15148559doi: 10.1007/s00223-004-0172-3google scholar: lookup
  33. Karsdal MA, Qvist P, Christiansen C, Tankó LB. Optimising antiresorptive therapies in postmenopausal women: why do we need to give due consideration to the degree of suppression?. Drugs 2006;66(15):1909-18.
    pubmed: 17100403doi: 10.2165/00003495-200666150-00002google scholar: lookup
  34. Kiviranta R, Morko J, Alatalo SL, NicAmhlaoibh R, Risteli J, Laitala-Leinonen T, Vuorio E. Impaired bone resorption in cathepsin K-deficient mice is partially compensated for by enhanced osteoclastogenesis and increased expression of other proteases via an increased RANKL/OPG ratio.. Bone 2005 Jan;36(1):159-72.
    pubmed: 15664014doi: 10.1016/j.bone.2004.09.020google scholar: lookup
  35. Lotinun S, Kiviranta R, Matsubara T, Alzate JA, Neff L, Lüth A, Koskivirta I, Kleuser B, Vacher J, Vuorio E, Horne WC, Baron R. Osteoclast-specific cathepsin K deletion stimulates S1P-dependent bone formation.. J Clin Invest 2013 Feb;123(2):666-81.
    pmc: PMC3561821pubmed: 23321671doi: 10.1172/jci64840google scholar: lookup
  36. Hochberg MC, Greenspan S, Wasnich RD, Miller P, Thompson DE, Ross PD. Changes in bone density and turnover explain the reductions in incidence of nonvertebral fractures that occur during treatment with antiresorptive agents.. J Clin Endocrinol Metab 2002 Apr;87(4):1586-92.
    pubmed: 11932287doi: 10.1210/jcem.87.4.8415google scholar: lookup
  37. Xiang A, Kanematsu M, Kumar S, Yamashita D, Kaise T, Kikkawa H, Asano S, Kinoshita M. Changes in micro-CT 3D bone parameters reflect effects of a potent cathepsin K inhibitor (SB-553484) on bone resorption and cortical bone formation in ovariectomized mice.. Bone 2007 May;40(5):1231-7.
    pubmed: 17347064doi: 10.1016/j.bone.2007.01.010google scholar: lookup
  38. Jerome C, Missbach M, Gamse R. Balicatib, a cathepsin K inhibitor, stimulates periosteal bone formation in monkeys.. Osteoporos Int 2011 Dec;22(12):3001-11.
    pubmed: 21308366doi: 10.1007/s00198-011-1529-xgoogle scholar: lookup
  39. Pennypacker BL, Chen CM, Zheng H, Shih MS, Belfast M, Samadfam R, Duong LT. Inhibition of cathepsin K increases modeling-based bone formation, and improves cortical dimension and strength in adult ovariectomized monkeys.. J Bone Miner Res 2014 Aug;29(8):1847-58.
    pubmed: 24591096doi: 10.1002/jbmr.2211google scholar: lookup
  40. Schaller S, Henriksen K, Sveigaard C, Heegaard AM, Hélix N, Stahlhut M, Ovejero MC, Johansen JV, Solberg H, Andersen TL, Hougaard D, Berryman M, Shiødt CB, Sørensen BH, Lichtenberg J, Christophersen P, Foged NT, Delaissé JM, Engsig MT, Karsdal MA. The chloride channel inhibitor NS3736 [corrected] prevents bone resorption in ovariectomized rats without changing bone formation.. J Bone Miner Res 2004 Jul;19(7):1144-53.
    pubmed: 15176998doi: 10.1359/jbmr.040302google scholar: lookup
  41. Soto SA, Barbará AC. Bisphosphonates: pharmacology and clinical approach to their use in equine osteoarticular diseases. J. Equ. Vet. Sci. 2014;34(6):727–37.
  42. Bartl R, Frisch B, von Tresckow E, Bartl C. Bisphosphonates in medical practice: actions-side effects-indications-strategies. Springer. Science & Business Media 2007.
  43. Piccione M, Durgam S, Stewart M. Impact of Bisphosphonate on Osteoprogenitor Cell Differentiation. Enliven: J Stem Cells Regen Med 2016;3(2003).
  44. Açil Y, Möller B, Niehoff P, Rachko K, Gassling V, Wiltfang J, Simon MJ. The cytotoxic effects of three different bisphosphonates in-vitro on human gingival fibroblasts, osteoblasts and osteogenic sarcoma cells.. J Craniomaxillofac Surg 2012 Dec;40(8):e229-35.
    pubmed: 22082730doi: 10.1016/j.jcms.2011.10.024google scholar: lookup
  45. Hughes DE, MacDonald BR, Russell RG, Gowen M. Inhibition of osteoclast-like cell formation by bisphosphonates in long-term cultures of human bone marrow.. J Clin Invest 1989 Jun;83(6):1930-5.
    pmc: PMC303914pubmed: 2524504doi: 10.1172/jci114100google scholar: lookup

Citations

This article has been cited 3 times.
  1. Wu F, Wu Z, Ye Z, Niu G, Ma Z, Zhang P. PLGA/BGP/Nef porous composite restrains osteoclasts by inhibiting the NF-κB pathway, enhances IGF-1-mediated osteogenic differentiation and promotes bone regeneration.. J Biol Eng 2023 Jul 17;17(1):45.
    doi: 10.1186/s13036-023-00354-8pubmed: 37461106google scholar: lookup
  2. Zou N, Liu R, Li C. Cathepsin K(+) Non-Osteoclast Cells in the Skeletal System: Function, Models, Identity, and Therapeutic Implications.. Front Cell Dev Biol 2022;10:818462.
    doi: 10.3389/fcell.2022.818462pubmed: 35912093google scholar: lookup
  3. Zhang W, Dong Z, Li D, Li B, Liu Y, Zheng X, Liu H, Zhou H, Hu K, Xue Y. Cathepsin K deficiency promotes alveolar bone regeneration by promoting jaw bone marrow mesenchymal stem cells proliferation and differentiation via glycolysis pathway.. Cell Prolif 2021 Jul;54(7):e13058.
    doi: 10.1111/cpr.13058pubmed: 34053135google scholar: lookup
Subscribe to our newsletter
Join 99,357 horse owners like you who receive our email updates on horse health and nutrition.